What We're Reading: Page 100
Industry reads hand-picked by our editors
Oct 11, 2022
-
The Washington Post
For decades, fear and failure in the hunt for an RSV vaccine. Now, success.
-
The Wall Street Journal
Bio-Rad Laboratories in Talks to Combine With Qiagen
-
Reuters
U.S. finds new quality problems at Lilly drug factory
-
Stat News
For tiny biotech, Alzheimer’s drug means vindication and a fortune
Oct 10, 2022
-
The Wall Street Journal
CEO of Biotech Lobbying Group BIO on Leave Amid Clash Over Direction
-
Bloomberg
ADHD Drug Adderall Supply Delays Likely to Continue for 2-3 Months, Teva Says
-
Stat News
Biogen eyes former J&J exec as a leading candidate to be CEO
-
Endpoints News
‘False hopes’: FDA releases briefing docs on controversial preterm birth med Makena ahead of adcomm
Oct 07, 2022
Oct 06, 2022
Oct 05, 2022
Oct 04, 2022
-
USA Today
One big change is coming to clinical drug trials, and it’s ‘no longer lip service’
-
Science
‘Cycles of panic and neglect’: Head of Pandemic Prevention Institute explains its early death
-
The Wall Street Journal
World’s Most Expensive Drugs Can’t Cure What Ails This Biotech
-
Endpoints News
FTC chair Lina Khan pledges to use all tools to investigate PBMs
-
BioPharma Dive
5 FDA decisions to watch in the fourth quarter
Oct 03, 2022
-
The New York Times
Nobel Prize in Physiology or Medicine Is Awarded to Svante Pääbo
-
Financial Times
Moderna refused China request to reveal vaccine technology
-
Axios
HHS: Prices of 1,200 drugs rose faster than inflation
-
Evaluate Vantage
FDA scrutiny now hits Parp inhibitors
Previous
